Knight Expands Team

MONTREAL, QUEBEC--(Marketwired - Aug. 26, 2014) - Knight Therapeutics Inc. (TSX:GUD) ("Knight") announced today (1) the appointment of Amal Khouri to the position of Vice President of Business Development and (2) the appointment of Sylvie Tendler to Knight's Board of Directors. "Both Amal and Sylvie are proven pharmaceutical executives and expand our capacity to secure the rights to innovative pharmaceuticals that improve the health of Canadians", said Jonathan Ross Goodman, President and CEO of Knight.

About Amal Khouri

Prior to joining Knight, Amal Khouri worked at Novartis Pharma for over 7 years, where she held multiple positions within the global business development and licensing team in Basel, Switzerland. Before joining Novartis, Amal worked in business development at Paladin Labs in roles with increasing responsibilities. Amal holds a B.Sc. in Biochemistry from McGill University and an M.B.A. from the University of Ottawa.

About Sylvie Tendler

Sylvie Tendler is a leading pharmaceutical market research specialist. In 2001, she founded The Tendler Group, a custom pharma marketing research consulting company which served 12 of the Top 20 global pharmaceutical companies. Sylvie led The Tendler Group until its sale to IntrinsiQ LLC in 2007 where she remained as President of IntrinsiQ Tendler until 2010. Sylvie has hand-on experience conducting global primary research in the top 5 EU markets, as well as USA, Brazil and Mexico and has been involved in the development and launch of blockbuster prescription products across therapeutic categories. Sylvie holds a Master's degree in International Management from the University of Maryland.

About Knight Therapeutics Inc.

Knight Therapeutics Inc., headquartered in Montreal, Canada, is a specialty pharmaceutical company focused on acquiring or in-licensing innovative pharmaceutical products for the Canadian and world markets. Knight Therapeutics' shares began trading on the TSX-V on March 3, 2014 and graduated to the TSX on April 29, 2014 under the symbol GUD. For more information about Knight Therapeutics Inc., please visit the company's web site at www.gud-knight.com or at www.sedar.com.

Knight Therapeutics Forward-Looking Statement

This press release may contain forward-looking statements and predictions. These forward-looking statements, by their nature, necessarily involve risks and uncertainties that could cause actual results to differ materially from those contemplated by the forward-looking statements. The company considers the assumptions on which these forward-looking statements are based to be reasonable at the time they were prepared, but cautions that these assumptions regarding the future events, many of which are beyond the control of the company and its subsidiaries, may ultimately prove to be incorrect. Factors and risks, which could cause actual results to differ materially from current expectations, are discussed in the company's final application for listing on the TSX Venture Exchange and in two short form prospectuses which can be found on SEDAR at www.sedar.com, which investors should consult for additional information. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information or future events and except as required by law.